Liposome-Based Drug Delivery Systems in Cancer Immunotherapy.
Zili GuCandido G Da SilvaKoen Van der MaadenFerry OssendorpLuis J CruzPublished in: Pharmaceutics (2020)
Cancer immunotherapy has shown remarkable progress in recent years. Nanocarriers, such as liposomes, have favorable advantages with the potential to further improve cancer immunotherapy and even stronger immune responses by improving cell type-specific delivery and enhancing drug efficacy. Liposomes can offer solutions to common problems faced by several cancer immunotherapies, including the following: (1) Vaccination: Liposomes can improve the delivery of antigens and other stimulatory molecules to antigen-presenting cells or T cells; (2) Tumor normalization: Liposomes can deliver drugs selectively to the tumor microenvironment to overcome the immune-suppressive state; (3) Rewiring of tumor signaling: Liposomes can be used for the delivery of specific drugs to specific cell types to correct or modulate pathways to facilitate better anti-tumor immune responses; (4) Combinational therapy: Liposomes are ideal vehicles for the simultaneous delivery of drugs to be combined with other therapies, including chemotherapy, radiotherapy, and phototherapy. In this review, different liposomal systems specifically developed for immunomodulation in cancer are summarized and discussed.
Keyphrases
- drug delivery
- drug release
- immune response
- papillary thyroid
- cancer therapy
- dendritic cells
- mental health
- early stage
- radiation therapy
- squamous cell carcinoma
- induced apoptosis
- single cell
- emergency department
- radiation induced
- lymph node metastasis
- climate change
- case report
- drug induced
- mesenchymal stem cells
- childhood cancer
- rectal cancer
- cell therapy
- endoplasmic reticulum stress
- signaling pathway
- pi k akt